PLGF Antibody / PGF / Placenta Growth Factor

ELISA (order BSA/sodium azide-free format for coating),Functional studies (order BSA/sodium azide-free format)

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the PLGF antibody to be titered up or down for optimal performance.

The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described. These include fibroblast-, platelet derived-, vascular endothelial- and placenta- growth factor (PLGF). Like vascular endothelial growth factor, several PLGF variants have been shown to arise from alternative mRNA splicings. Evidence has suggested VEGF to be an obligatory component in PLGF signaling. While VEGF homodimers and VEGF/PLGF heterodimers function as potent mediators of mitogenic and chemotactic responses in endothelial cells, PLGF homodimers are effectual only at extremely high concentrations. Indeed, many of the physiological effects attributed to VEGF may actually be a result of VEGF/PLGF. VEGF and PLGF share a common receptor, Flt-1, and may also activate Flk-1/KDR.

Purified

1 mg/ml in 1X PBS; BSA free, sodium azide free

5228

Recombinant human protein was used as the immunogen for this PLGF antibody.

This PLGF antibody is available for research use only.

Secreted (extracellular)

Protein G purified PLGF antibody